Chlamydia trachomatis

Chlamydia trachomatis is a gram-negative bacterium that replicates exclusively within a host cell, making it an obligate intracellular pathogen. The bacterium is largely dependent on the host cell for metabolic intermediates and energy, particularly in the form of adenosine triphosphate (ATP). Other metabolites including amino acids, nucleotides, and lipids are also transported from the host. A critical enzyme involved in glycolysis, hexokinase, is absent in C. trachomatis, preventing the production of glucose-6-phosphate (G6P). Instead, G6P from the host cell is taken up by the metabolically active reticulate bodies (RBs) through a G6P transporter (UhpC antiporter). Excess glycolytic products are, in turn, brought into the host's PPP to create nucleotides and for biosynthesis, again feeding the growth needs of the bacterium. This type of growth is very similar to the Warburg effect observed in cancer cells. ==Life cycle==

Like other Chlamydia species, C. trachomatis has a life cycle consisting of two morphologically distinct forms. First, C. trachomatis attaches to a new host cell as a small spore-like form called the elementary body. ==Classification==

Chlamydia trachomatis are bacteria in the genus Chlamydia, a group of obligate intracellular parasites of eukaryotic cells. Chlamydia trachomatis strains are generally divided into three biovars based on the type of human disease they cause. Each biovar is further subdivided into several serovars based on the surface antigens recognized by the immune system. Serovars D through K infect the genital tract, causing pelvic inflammatory disease, ectopic pregnancies, and infertility. Serovars L1 through L3 cause an invasive infection of the lymph nodes near the genitals, called lymphogranuloma venereum. C. trachomatis along with C. pneumoniae have been found to infect humans to a greater extent. C. trachomatis exclusively infects humans. C. pneumoniae is found to also infect horses, marsupials, and frogs. Some of the other species can have a considerable impact on human health due to their known zoonotic transmission. }} ==Role in disease==

Clinical signs and symptoms of C. trachomatis infection in the genitalia present as the chlamydia infection, which may be asymptomatic or may resemble a gonorrhea infection. Chlamydia trachomatis is the single most important infectious agent associated with blindness (trachoma), and it also affects the eyes in the form of inclusion conjunctivitis and is responsible for about 19% of adult cases of conjunctivitis. Chlamydia trachomatis in the lungs presents as the chlamydia pneumoniae respiratory infection and can affect all ages. Pathogenesis Elementary bodies are generally present in the semen of infected men and vaginal secretions of infected women. The plasmid gene protein 3 (pgp3) has been linked to the establishment of persistent infection within the genital tract by suppressing the host immune response. Polymorphic outer membrane proteins (Pmp proteins) on the surface of C. trachomatis use tropism to bind specific host cell receptors, which in turn initiates infection. Pmp proteins B, D, and H have been most associated with eliciting a pro-inflammatory response through the release of cytokines. CPAF (Chlamydia Protease-like Activity Factor) functions by preventing the host from triggering the proper immune response. C. trachomatis use of CPAF targets and cleaves proteins that restructure the Golgi apparatus and activate DNA repair so that C. trachomatis is able to use the host cell machinery and proteins to its advantage. Presentation Most people infected with C. trachomatis are asymptomatic. However, the bacteria can present in one of three ways: genitourinary (genitals), pulmonary (lungs), and ocular (eyes). Genitourinary cases can include genital discharge, vaginal bleeding, itchiness (pruritus), painful urination (dysuria), among other symptoms. Often, symptoms are similar to those of a urinary tract infection. When C. trachomatis presents in the eye in the form of trachoma, it begins by gradually thickening the eyelids and eventually begins to pull the eyelashes into the eyelid. In the form of inclusion conjunctivitis, the infection presents with redness, swelling, mucopurulent discharge from the eye, and most other symptoms associated with adult conjunctivitis. Prevalence Three times as many women are diagnosed with genitourinary C. trachomatis infections as men. Women aged 15–19 have the highest prevalence, followed by women aged 20–24, although the rate of increase of diagnosis is greater for men than for women. Risk factors for genitourinary infections include unprotected sex with multiple partners, lack of condom use, and low socioeconomic status living in urban areas. Trachoma is the primary source of infectious blindness in some parts of rural Africa and Asia and is a neglected tropical disease that has been targeted by the World Health Organization for elimination by 2020. Inclusion conjunctivitis from C. trachomatis is responsible for about 19% of adult cases of conjunctivitis. and tetracycline. Tetracycline is the most preferred antibiotic to treat C.trachomatis and has the highest success rate. Azithromycin and doxycycline have equal efficacy to treat C. trachomatis with 97 and 98 percent success, respectively. Azithromycin is dosed as a 1 gram tablet that is taken by mouth as a single dose, primarily to help with concerns of non-adherence. Erythromycin is less preferred as it may cause gastrointestinal side effects, which can lead to non-adherence. Levofloxacin and ofloxacin are generally no better than azithromycin or doxycycline and are more expensive. Tetracycline is not used because some children and even adults can not withstand the drug, causing harm to the mother and fetus. Laboratory tests Chlamydia species are readily identified and distinguished from other Chlamydia species using DNA-based tests. Tests for Chlamydia can be ordered from a doctor, a lab or online. Most strains of C. trachomatis are recognized by monoclonal antibodies (mAbs) to epitopes in the VS4 region of MOMP. However, these mAbs may also cross-react with two other Chlamydia species, C. suis and C. muridarum. • Nucleic acid amplification tests (NAATs) tests find the genetic material (DNA) of Chlamydia bacteria. These tests are the most sensitive tests available, meaning they are very accurate and are unlikely to have false-negative test results. A polymerase chain reaction (PCR) test is an example of a nucleic acid amplification test. This test can also be done on a urine sample, urethral swabs in men, or cervical or vaginal swabs in women. • Nucleic acid hybridization tests (DNA probe test) also find Chlamydia DNA. A probe test is very accurate but is not as sensitive as NAATs. • Enzyme-linked immunosorbent assay (ELISA, EIA) finds substances (Chlamydia antigens) that trigger the immune system to fight Chlamydia infection. Chlamydia Elementary body (EB)-ELISA could be used to stratify different stages of infection based upon Immunoglobulin-γ status of the infected individuals • Direct fluorescent antibody test also finds Chlamydia antigens. • Chlamydia cell culture is a test in which the suspected Chlamydia sample is grown in a vial of cells. The pathogen infects the cells, and after a set incubation time (48 hours), the vials are stained and viewed on a fluorescent light microscope. Cell culture is more expensive and takes longer (two days) than the other tests. The culture must be grown in a laboratory. ==Research==

Studies have revealed antibiotic resistance in Chlamydia trachomatis. Mutations in the 23S rRNA gene, including A2057G and A2059G, have been identified as significant contributors to resistance against azithromycin, a commonly used treatment. This resistance is linked to treatment failures and persistent infections, necessitating ongoing research into alternative antibiotics, such as moxifloxacin, as well as non-antibiotic approaches like bacteriophage therapy. These innovations aim to combat resistance while reducing the overall burden of antibiotic misuse, which has been closely associated with the rise of resistant strains in C. trachomatis populations. Additionally, diagnostic improvements have played a vital role in identifying C. trachomatis infections more efficiently. Nucleic acid amplification tests (NAATs), such as DNA- and RNA-based tests, have shown high sensitivity and specificity, making them the gold standard for detecting asymptomatic infections. NAATs have facilitated broader screening programs, particularly in high-risk populations, and are integral to public health initiatives aimed at controlling the spread of C. trachomatis. Research continues into point-of-care diagnostic tools, which promise faster results and greater accessibility, especially in low-resource settings. Studies have challenged traditional assumptions about the transmission and persistence of C. trachomatis in the human body. In a study of heterosexual women with no history of receptive anal intercourse, researchers identified highly viable C. trachomatis in deep rectal samples (using a proctoscope), suggesting that gastrointestinal colonization may occur through non-anal routes such as vaginorectal transfer or oral exposure. Notably, the rectal and cervical strains often carried distinct MLST types, indicating that rectal infections may persist independently of concurrent genital infection. These findings point to the gastrointestinal tract as a potential long-term reservoir for C. trachomatis, with implications for diagnostics, treatment strategies, and reinfection risk. Longitudinal molecular epidemiology studies have demonstrated that the cervicovaginal microbiome influences susceptibility to Chlamydia trachomatis infection and its natural history. In particular, molecularly defined subtypes of bacterial vaginosis (i.e., mBV-A) characterized by increased microbial diversity and enrichment of anaerobic taxa (particularly Candidatus Lachnocurva vaginae), have been associated with increased risk of incident infection, reinfection following treatment, and clinical sequelae including pelvic inflammatory disease and miscarriage. This finding support a model in which host-microbe interaction contribute to infection dynamics beyond traditional risk factors. In the area of vaccine development, creating an effective vaccine for C. trachomatis has proven challenging due to the complex immune responses the bacterium elicits. Subunit vaccines, which target outer membrane proteins like MOMP (Major Outer Membrane Protein) and polymorphic membrane proteins (Pmp), are being explored in both animal models and early human trials. While these vaccines show promise in inducing partial immunity in murine models, further research is needed to evaluate their efficacy in humans. The goal is to develop a vaccine that can prevent reinfection without causing harmful inflammatory responses. ==History==

Chlamydia trachomatis was first described in 1907 by Stanislaus von Prowazek and Ludwig Halberstädter in scrapings from trachoma cases. Thinking they had discovered a "mantled protozoan", they named the organism "Chlamydozoa" from the Greek "Chlamys" meaning mantle. Subsequent studies determined that C. trachomatis synthesizes both muramic acid and peptidoglycan, but relegates it to the microbe's division septum and does not utilize it for construction of a cell wall. The bacterium is still classified as gram-negative. This was a significant milestone because it became possible to preserve these agents, which could then be used for future genomic and phylogenetic studies. The isolation of C. trachomatis coined the term isolate to describe how C. trachomatis has been isolated from an in vivo setting into a "strain" in cell culture. Only a few "isolates" have been studied in detail, limiting the information that can be found on the evolutionary history of C. trachomatis. == Evolution ==

In the 1990s it was shown that there are several species of Chlamydia. Chlamydia trachomatis was first described in historical records in Ebers papyrus written between 1553 and 1550 BC. In the ancient world, it was known as the blinding disease trachoma. The disease may have been closely linked with humans and likely predated civilization. It is now known that C. trachomatis comprises 19 serovars which are identified by monoclonal antibodies that react to epitopes on the major outer-membrane protein (MOMP). Comparison of amino acid sequences reveals that MOMP contains four variable segments: S1,2 ,3 and 4. Different variants of the gene that encodes for MOMP, differentiate the genotypes of the different serovars. The antigenic relatedness of the serovars reflects the homology levels of DNA between MOMP genes, especially within these segments. Furthermore, there have been over 220 Chlamydia vaccine trials done on mice and other non-human host species to target C. muridarum and C. trachomatis strains. However, it has been difficult to translate these results to the human species due to physiological and anatomical differences. Future trials are working with closely related species to humans. ==See also==